Skip to main content

facebook twitter google google | 44 Hudson Street New York, NY 10013 |

Category: Fat Grafting Research

Sydney Coleman Featured in the ASPS 2014 Official Program

Posted October 29, 2014

Sydney Coleman is highlighted in the 2014 Program of the American Society of Plastic Surgeons for receiving the ASPS coveted Trustees Special Achievement Award (see below) A Description of the ASPS Trustees Special Achievement Award and Sydney Coleman is offered on Page A6 of the Official Program 2014 of the ASPS About the ASPS Trustees […]

Read More

Highest Award given to Sydney Coleman

Posted October 27, 2014

The Board of Trustees of the American Society of Plastic Surgery bestowed the greatest honor given by the ASPS on Sydney Coleman Linda Phillips awards the Highest Honor bestowed by the ASPS The letter informing him of the decision follows: Subject: Trustees’ Award Dear Dr. Coleman, As the Chair of the ASPS trustees, it is […]

Read More

Sydney Coleman Video on Fat Grafts, Stem Cells & Regenerative Surgery

Posted August 20, 2013

Interview with Sydney Coleman, MD Sydney Reese Coleman is the physician who first observed and announced to the scientific community the amazing regenerative ability of fat grafts and the associated stem cells. Beginning in 1987, he has developed procedures that utilize transplanted fat to not only fill faces and bodies, but also to harness the […]

Read More

BRAVA Breast Fat Graft Study OK by FDA

Posted June 27, 2013

For those who were concerned about the temporary injunction on the study involving Brava use in association with fat grafting there is good news.  The FDA has completed its review of the IDE application for the Brava Clinical Study: Breast Reconstruction and Augmentation with the Brave Enhanced Autologous Fat Micro Grafting as of May 3, […]

Read More

BRAVA Breast Expansion Device Reclassified by FDA

Posted April 19, 2013

FDA asks for Investigational Device Exemption for BRAVA Studies The FDA, in a surprising move, has re-classified the BRAVA breast expansion device into a higher risk category for the ongoing BRAVA clinical trials.  We want to assure our patients (those who are currently using the device, have used it in the past, or who contemplate […]

Read More